

Highly accurate, comprehensive results you can trust



**The Panorama<sup>®</sup> Prenatal Screen identifies:**

**Whole Chromosome Conditions**

Trisomy 21, 18, 13

Monosomy X

Sex chromosome trisomies

Triploidy

Complete molar pregnancy

**Optional**

22q11.2 deletion syndrome

Additional microdeletion syndromes

Fetal sex



# A superior first-line screening test for all women

Panorama screens for more chromosomal abnormalities, with greater accuracy


Compared to First Trimester Screening, Panorama has higher sensitivity and lower false positive rate for the conditions screened.

## HIGHLY ACCURATE AND COMPREHENSIVE SCREENING

| Condition  | First Trim. Screen <sup>6</sup>    | Panorama <sup>3,7</sup>            |
|--|------------------------------------|------------------------------------|
|  | Sensitivity<br>False Positive Rate | Sensitivity<br>False Positive Rate |
| <b>Trisomy 21</b><br><i>Down Syndrome</i>        | 79%<br>5%                          | >99.9 (83/83)<br>0%                |
| <b>Trisomy 18</b><br><i>Edwards Syndrome</i>     | 80%<br>0.3%                        | 96.4% (27/28)<br><0.1%             |
| <b>Trisomy 13</b><br><i>Patau Syndrome</i>       | 50%<br>0.3%                        | >99% (13/13)<br>0%                 |
| <b>Monosomy X</b><br><i>Turner Syndrome</i>      | <i>Does not screen for</i>         | 92.9% (13/14)<br><0.1%             |
| <b>Triploidy</b>                                 | <i>Does not screen for</i>         | >99% (8/8)                         |
| <b>Female</b>                                    | <i>Does not determine</i>          | >99.9% (469/469)<br>0%             |
| <b>Male</b>                                      | <i>Does not determine</i>          | >99.9% (533/533)<br>0%             |
| <b>Optional Microdeletion Syndromes</b>          |                                    |                                    |
| <b>22q11.2 deletion</b> <i>DiGeorge syndrome</i> | <i>Does not screen for</i>         | 95.7% (45/47)                      |
| <b>Additional microdeletions*</b>                | <i>Does not screen for</i>         | 93.8 - >99%                        |

\*Additional microdeletions include: Angelman, Cri-du-chat, 1p36 deletion & Prader-Willi

Higher PPV = less anxiety for patients



# Non-invasive method with more informative results

## Discussing NIPT with your patients, per ACOG guidelines<sup>2</sup>



*“Testing for chromosome abnormalities is optional.”*

*“If you would like to know the risk of your baby having a chromosome abnormality, **screening options** are available.”*

*“If you want to know for sure about chromosome abnormalities, you can opt for **diagnostic testing.**”*

Least Information


Most Information

|             | No testing  | Traditional Serum Screen  | NIPT   | CVS/AMNIO  |
|-------------|---|---|--|--|
| BENEFITS    | <ul style="list-style-type: none"> <li>- Less anxiety for women who may worry about testing</li> <li>- No difficult decisions to make in case of abnormal results</li> </ul>                              | <ul style="list-style-type: none"> <li>- Non-invasive</li> <li>- If performed in 2nd trimester, screens for certain birth defects like spina bifida</li> </ul>  | <ul style="list-style-type: none"> <li>- Non-invasive</li> <li>- Screens for more conditions*</li> <li>- Higher sensitivity &amp; positive predictive value*</li> <li>- Most women receive low risk results,<sup>4</sup> thereby reducing anxiety</li> <li>- Screen as early as 9 weeks</li> </ul> | <ul style="list-style-type: none"> <li>- Definitive results</li> <li>- More comprehensive than NIPT or serum screening</li> <li>- Ability to plan for baby's care in case of abnormal results</li> </ul> |
| LIMITATIONS | <ul style="list-style-type: none"> <li>- Inability to plan medically, financially &amp; emotionally</li> <li>- Missed opportunity to engage with specialists &amp; community support resources</li> </ul> | <ul style="list-style-type: none"> <li>- Not diagnostic</li> <li>- Limited to Trisomy 21, 18 and 13</li> <li>- Lower sensitivity, higher false positive rate and lower positive predictive value than NIPT</li> </ul> | <ul style="list-style-type: none"> <li>- Not diagnostic; false positives and false negatives do occur</li> <li>- Does not screen for all chromosome abnormalities</li> <li>- May not be able to report results in a small number of patients</li> </ul>  | <ul style="list-style-type: none"> <li>- Invasive; small risk of miscarriage</li> <li>- Amnio results not available until 2nd trimester</li> <li>- Possible results of uncertain significance</li> </ul> |



\*Compared to serum screening

# High accuracy through SNP-based NIPT methodology

## Panorama targets single nucleotide polymorphisms (SNPs) in cell-free DNA



## Unique clinical benefits due to SNP-based methodology

| <br>REDUCES FALSE POSITIVES COMPARED TO OTHER NIPT METHODS   | <br>IDENTIFIES CONDITIONS ASSOCIATED WITH COMPLICATIONS FOR MOM  |
|---|---|
| <p><b>VANISHING TWIN</b></p> <p>Only Panorama can identify a vanishing twin, which may contribute to &gt;15% of false positive results with other NIPTs.<sup>8,9</sup></p> <p><b>&gt;99.9% FETAL SEX ACCURACY<sup>3</sup></b></p> <p>No incorrect gender calls in validation studies. Less anxiety and unnecessary work-up for patients.</p> <p><b>MATERNAL ABNORMALITIES</b></p> <p>Only Panorama minimizes the chance that a maternal abnormality leads to a false positive result. This is a significant cause of false positives when using other NIPTs.<sup>10</sup></p> | <p><b>COMPLETE MOLAR PREGNANCY</b></p> <p>Only Panorama identifies complete molar pregnancy, which can be associated with preeclampsia, hemorrhage, and gestational trophoblastic neoplasia, and rarely, metastatic choriocarcinoma.<sup>11</sup></p> <p><b>TRIPLOIDY</b></p> <p>Only Panorama identifies triploidy, which is often associated with stillbirth, severe birth defects and preeclampsia.<sup>8,12</sup></p> |

## Measuring fetal fraction is critical for high-confidence NIPT results

- ✓ NIPTs target fetal (placental) DNA for determining fetal risk of chromosomal abnormalities
- ✓ ACOG emphasizes the importance of fetal fraction as “essential for accurate test results”<sup>2</sup>
- ✓ Failure to measure fetal fraction can correlate to false negative results<sup>13</sup>

## Extensive clinical experience around the world<sup>14</sup>

**>500,000**

... Panorama cases have been reported.

**1 out of 5**

... OBGYN/MFM physicians have ordered Panorama in the US alone.

**60+**

...countries around the world have Panorama commercially available.

# The next generation of non-invasive prenatal screening

Non-invasive prenatal testing (NIPT) analyzes cell-free DNA in a pregnant woman's blood to estimate the risk of fetal chromosomal abnormalities.

Panorama® uniquely distinguishes between fetal (placental) and maternal cell-free DNA, leading to fewer false positives and a more comprehensive basic panel compared with other screening methods.

## Professional societies recognize the role of NIPT



Considers NIPT appropriate as primary screening test for all women.<sup>1</sup>



Recommends providers educate patients on benefits and limitations of NIPT and other testing options.<sup>2</sup>

## Panorama has validated performance in both high and average risk pregnancies

|                | Validation<br>T21, T18, T13 and MX <sup>3</sup> |                    | Clinical Outcomes<br>T21, T18, T13 and MX <sup>4</sup><br>(Aneuploidy Incidence) |
|----------------|---|--------------------|--|
|                | Sensitivity                                     | Specificity        | PPV*   |
| High Risk**    | 98.0%<br>(98/100)                               | 99.5%<br>(389/391) | 82.9%<br>(2.4%)  |
| Average Risk** | 100%<br>(5/5)                                   | 100%<br>(469/469)  | 87.2%<br>(1.0%)  |

\* PPV = positive predictive value.

\*\* For the purposes of calculating PPV, high risk was defined as women ≥35 years old at delivery, and average risk was defined as women <35 years old at delivery.

## Panorama's advantages, when compared to traditional maternal serum screening



**Higher sensitivity**  
for the conditions  
screened







**Fewer false positives**  
fewer unnecessary  
invasive procedures<sup>5</sup>



**More conditions included**  
more informative results

# Support every step of the way

|  |   |  |  |
|--|---|--|--|
|   |    |    |   |
| <p><b>SEAMLESS INTEGRATION</b><br/>into your workflow</p>  | <p><b>SAFE, EASY</b><br/>sample collection</p>  | <p><b>ADVANCED TECHNOLOGY</b><br/>for results you can trust</p>  | <p><b>FAST, CLEAR REPORTING</b><br/>with support from our team</p>   |
| <ul style="list-style-type: none"> <li>- You can offer Panorama as early as 9 weeks gestation.</li> <li>- Patients can learn more about our tests and access complimentary information sessions throughout their screening process on myNatera.com.</li> </ul> | <ul style="list-style-type: none"> <li>- Your samples can be sent via a pre-packaged, post-marked kit to Natera.</li> <li>- You can also set up a courier service through Natera.</li> <li>- Patients can access Natera phlebotomy services at myNatera.com.</li> </ul> | <ul style="list-style-type: none"> <li>- Panorama utilizes SNP-based sequencing and Natera's proprietary algorithms to deliver highly accurate and comprehensive results.</li> </ul> | <ul style="list-style-type: none"> <li>- Results come within 7-10 calendar days through Natera Connect with a release-to-patient function.</li> <li>- Reports include risk score, PPV (if high risk) and fetal fraction to give you confidence in the results and the care plan for your patient.</li> </ul> |

## Commonly Asked Questions

### WHAT CONDITIONS DOES PANORAMA SCREEN FOR?

#### Whole Chromosome Conditions

- Trisomies 21, 18 and 13
- Monosomy X
- Sex chromosome trisomies
- Triploidy
- Complete molar pregnancy

#### Optional

- 22q11.2 deletion
- Angelman
- Cri-du-chat
- 1p36 deletion
- Prader-Willi
- Fetal sex

### HOW MUCH WILL IT COST FOR MY PATIENT?

Panorama is covered as an in-network laboratory by many health plans. To understand the cost to your patient, visit **NateraCost.com**. Our team can also work with your patient to discuss affordable payment options.

### HOW DO I REQUEST MORE TEST KITS?

Panorama collection kits are provided to the clinic at no charge and can be stored on-site.

#### To order a Panorama Prenatal Screen collection kit

**CLICK:** via Natera Connect    **CALL:** (650) 249.9090

**VISIT:** NateraOrder.com    **EMAIL:** support@natera.com



natera | 201 Industrial Road, Suite 410 | San Carlos, CA 94070 | 1-650-249-9090 | Fax 1-650-730-2272

This test was developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. © Natera 2016 All Rights Reserved